Acute Sialadenitis in Children and Adolescents: CT Findings and Clinical Manifestations according to Glandular Involvement

2008 ◽  
Vol 59 (3) ◽  
pp. 155
Author(s):  
A Leum Lee ◽  
Young Tong Kim ◽  
Jong Kyu Han ◽  
Sung Shick Jou ◽  
Du Shin Jung
Keyword(s):  
Children And Adolescents ◽  
Clinical Manifestations ◽  
Ct Findings

scholarly journals POS1199 CLINICAL MANIFESTATIONS OF SARS-CoV2 INFECTIONS IN CHILDREN AND ADOLESCENTS WITH RHEUMATIC AND MUSCULUSKELETAL DISEASES – SURVEY DATA FROM GERMANY

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 882.1-882
Author(s):  
C. Sengler ◽  
S. Eulert ◽  
M. Niewerth ◽  
T. Kallinich ◽  
H. Wittkowski ◽  
...  
Keyword(s):  
Disease Activity ◽  
Children And Adolescents ◽  
Symptom Onset ◽  
Clinical Manifestations ◽  
Virus Detection ◽  
German Society ◽  
Underlying Disease ◽  
Common Symptom ◽  
Disease Course ◽  
Cardiorespiratory Failure

Background:Although children and adolescents are less likely to develop COVID-19 and generally show milder disease courses, it is unclear what impact the SARS-CoV2 infection has on children and adolescents with rheumatic and musculoskeletal disease (RMD). Due to their underlying disease as well as therapeutic immunosuppression these patients may be at higher risk of being more severely affected by SARS-CoV2. Furthermore, SARS-CoV2 infection might trigger a flare of the underlying disease.Objectives:To evaluate clinical characteristics and disease course of COVID-19 in children and adolescents with RMD and to analyze possible effects of SARS-CoV2 infection on the underlying disease under different therapeutic regimens.Methods:Data from juvenile patients with RMD recorded via the SARS-CoV2 questionnaire within the National Pediatric Rheumatology Database and the registry for hospitalized children and adolescents with COVID-19 of the German Society for Pediatric Infectious Diseases were analyzed. In addition to age, sex and diagnosis, information was collected about the date and method of a positive SARS-CoV2 testing, reason for testing, on clinical manifestations, disease course, treatment and outcome of COVID-19, on drug therapy at the time of virus detection, on disease activity (NRS 0 – 10, 0 = best) of the underlying disease at the last visit before and after the SARS-CoV2 infection.Results:From April 17th 2020 until January 25th 2021, data of 67 patients with RMD and confirmed SARS-CoV2 infection were collected. Mean age was 13.5 ± 3.9 years with equal sex distribution. The majority of patients were diagnosed with juvenile idiopathic arthritis (JIA, 64%), 12 (18%) patients had an autoinflammatory disease (FMF, CAPS, PFAPA, TRAPS) and 5 (7%) a connective tissue disease. Fifty-two patients (78%) were treated with a disease modifying antirheumatic drug (DMARD), 39% with a biological DMARD and 9% systemic glucocorticoids at the time of SARS-CoV-2 infection. Nineteen patients (28%) were tested for SARS-CoV-2 because of typical symptoms, the majority (67%) because of contact to an infected person. PCR was used most often (in 60 %).52 patients (78%) developed symptoms of COVID-19, 15 patients remained asymptomatic. The most common symptom of COVID-19 was rhinitis (42%) and fever (38%), followed by fatigue (34%), taste/smell disorder (33%), sore throat (27%) and cough (23%).Disease severity was graded as mild in 44 of 52 (85%) symptomatic patients, only two patients were hospitalized, one of whom required intensive care and died of cardiorespiratory failure 3 days after symptom onset. In 22 of 26 (85%) SARS-CoV2-positive patients, no relevant increase in disease activity (difference in NRS ≤ 1 before/after infection) of the underlying disease was observed 31 days after symptom onset (median, IQR 17-52 days). One patient, who had paused tocilizumab for 2 doses, experienced a flare of his seronegative polyarthritis 2 months after asymptomatic SARS-CoV-2 infection.Conclusion:In our cohort, the clinical picture of COVID-19 in children and adolescents with RMD was similar to that of healthy peers. The majority of patients showed mild disease course with good outcome under various medications, however, one patient with a severe course of COVID-19 died. In addition, SARS-CoV2 infection does not appear to have a relevant impact on the underlying disease activity, whereas discontinuation of therapy might pose a risk of flare.Disclosure of Interests:None declared.

Epidemiological profile of children and adolescents with COVID-19: a scoping review

2021 ◽  
Vol 74 (suppl 1) ◽  
Author(s):  
Fabiane Blanco Silva Bernardino ◽  
Lidiane Cristina da Silva Alencastro ◽  
Ronaldo Antonio da Silva ◽  
Antonia Dinágila do Nascimento Ribeiro ◽  
Geovane Roberto de Campos Castilho ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Scoping Review ◽  
World Literature ◽  
Clinical Manifestations ◽  
Laboratory Diagnosis ◽  
Hospital Length ◽  
Socioeconomic Conditions ◽  
Disease Condition ◽  
Epidemiological Profile ◽  
Group Sex

ABSTRACT Objective: to map the epidemiological profile of children and adolescents with COVID-19 in the world literature. Methods: a scoping review systematized by the Joanna Briggs Institute protocol in the PubMed/MEDLINE, CINAHL, Web of Science, Scopus, Science direct and Google Scholar databases. Articles with children and/or adolescents with laboratory diagnosis of COVID-19 were used. Results: thirty-two articles were included in the review. Most children and adolescents were male, with contamination by family transmission. The most frequent clinical manifestations were fever, cough and diarrhea. Ten studies cited pre-existing condition/disease, and hospital length ranged from one to twenty days. Three deaths were reported and no study presented race/color, education and socioeconomic conditions. Conclusion: it was possible to screen the epidemiological profile with information about age group, sex, probable contamination of the disease, clinical manifestations, presence of pre-existing disease/condition, hospitalization and deaths among children and adolescents with COVID-19.

Clinical manifestations in children and adolescents with corpus callosum abnormalities

2016 ◽  
Vol 263 (10) ◽  
pp. 1939-1945 ◽  
Author(s):  
Lucia Margari ◽  
Roberto Palumbi ◽  
Maria Gloria Campa ◽  
Francesca Felicia Operto ◽  
Maura Buttiglione ◽  
...  
Keyword(s):  
Corpus Callosum ◽  
Children And Adolescents ◽  
Clinical Manifestations

scholarly journals Clinical manifestations, treatment, and outcomes of children and adolescents with eosinophilic esophagitis

2013 ◽  
Vol 89 (2) ◽  
pp. 197-203 ◽  
Author(s):  
Maraci Rodrigues ◽  
Maria Fernanda M. D’Amico ◽  
Fatima Regina Almeida Patiño ◽  
Dorina Barbieri ◽  
Aderson Omar Mourão Cintra Damião ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Eosinophilic Esophagitis ◽  
Clinical Manifestations

Analysis of clinical manifestations in 20 children and adolescents with tuberous sclerosis complex

2011 ◽  
Vol 42 (S 01) ◽  
Author(s):  
RR Mettin ◽  
S Syrbe ◽  
MK Bernhard ◽  
H Elix ◽  
W Hirsch ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Tuberous Sclerosis ◽  
Tuberous Sclerosis Complex ◽  
Clinical Manifestations

Slipped Capital Femoral Epiphysis Without Hip Pain Leads to Missed Diagnosis

PEDIATRICS ◽  
1992 ◽  
Vol 89 (4) ◽  
pp. 660-662
Author(s):  
Carol A. Ledwith ◽  
Gary R. Fleisher
Keyword(s):  
Children And Adolescents ◽  
Slipped Capital Femoral Epiphysis ◽  
Clinical Manifestations ◽  
Hip Pain ◽  
Thigh Pain ◽  
Initial Visit ◽  
Missed Diagnosis ◽  
Prompt Diagnosis

Prompt diagnosis of slipped capital femoral epiphysis (SCFE) is dependent on recognition of variable clinical manifestations. The charts of 116 children and adolescents with SCFE were reviewed to identify characteristics of patients whose diagnosis was initially missed. Missed diagnosis was found in 34 patients (29%). Sixteen of the 34 whose diagnosis was missed had hip pain,while 58 of the 82 whose diagnosis was not missed had hip pain (P =.0157). Of the 34 patients with missed diagnosis, 15 patients had thigh pain. In comparison, of the 82 patients without missed diagnosis, 19 had thigh pain(P = .0241). It is concluded that SCFE is more likely to be missed at the initial visit if hip pain is absent or if thigh pain is present. This review indicates that despite the evidence that patients with SCFE frequently complain of symptoms other than hip pain, the disorder continues to be missed.

REFERENCE VALUES FOR THE CONCENTRATION OF TREC AND KREC IN CHILDREN AGED 1–17 YEARS

2021 ◽  
Vol 100 (6) ◽  
pp. 38-45
Author(s):  
I.V. Obraztsov ◽  
◽  
L.A. Fedorova ◽  
A.P. Prodeus ◽  
D.A. Kudlay ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Reference Values ◽  
Whole Blood ◽  
Peripheral Blood ◽  
Correct Diagnosis ◽  
Clinical Manifestations ◽  
Reference Intervals ◽  
Key Factor ◽  
Late Start ◽  
First Year Of Life

The clinical manifestations of immunodeficiency states (IDS), whether primary or secondary, are extremely nonspecific. The consequence of this is the belated setting of the correct diagnosis and, accordingly, the late start of the necessary therapy. Early detection of IDS is a key factor in the successful treatment of patients with these diseases. Determination of the concentration of TREC and KREC in whole blood and dry blood stains by real-time PCR has already proven its effectiveness for newborns and children in the first year of life. Objective of the study: to determine the concentration reference values of TREC and KREC in peripheral blood and dry spots in children and adolescents aged 1–17 years. Materials and methods of research: 162 conditionally healthy individuals were examined, including 64 at the age of 1–5 years, 47 – 6–11 years old and 51 – 12–17 years old. The concentration of TREC and KREC DNA in peripheral whole blood and dry blood spots on neonatal screening cards was assessed by PCR. Results: reference intervals and threshold values of TREC and KREC content in dry spots and in peripheral whole blood of children and adolescents aged 1–17 years were built and substantiated. Conclusion: the obtained reference values are very convenient for identifying patients with T- and/or B-cell lymphopenia, as well as monitoring the number of naive T- and B-lymphocytes in the peripheral blood of patients with already known diseases in wide pediatric practice.

scholarly journals COVID-19 infection in children and adolescents

2020 ◽  
Vol 81 (8) ◽  
pp. 1-10
Author(s):  
Meena Naja ◽  
Lucy Wedderburn ◽  
Coziana Ciurtin
Keyword(s):  
Children And Adolescents ◽  
Adult Population ◽  
Clinical Manifestations ◽  
Specific Treatment ◽  
Intensive Care Admission ◽  
The Uk ◽  
Inflammatory Syndrome ◽  
Case Basis ◽  
Index Cases ◽  
Paediatric Disease

The COVID-19 pandemic has predominantly affected the adult population. The disease is less well-defined in children (≤18 years). This review summarises the current understanding of the epidemiology, clinical manifestations, and management of COVID-19 in children and adolescents. The prevalence of COVID-19 is significantly lower in children than adults, but paediatric disease is likely underdiagnosed as a result of the high numbers of asymptomatic or mild cases. Children are vulnerable to family cluster outbreaks, but are unlikely to be index cases within a household. Vertical transmission or breast milk transmission are yet to be proven. Between 10 and 90% of paediatric COVID-19 cases are asymptomatic. Symptomatic cases typically present with mild symptoms, including cough, fever and sore throat. Intensive care admission and mortality are rare. Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 is a rare, but severe, newly emerging phenotype. At present, there is no specific treatment for COVID-19 in adults or children; management is usually supportive. For severe or critical disease, including paediatric multisystem inflammatory syndrome temporally associated with COVID-19, the decision to start antiviral or immunomodulatory therapy should be on a case-by-case basis; in the UK, this should be done within a clinical trial. Further research is needed into both the disease course and treatment of paediatric COVID-19.

scholarly journals Paroxysmal disorders in the long-term after traumatic brain injury in children and adolescents

2019 ◽  
Vol 10 (4) ◽  
pp. 72-82
Author(s):  
N. N. Zavadenko ◽  
Yu. E. Nesterovskiy ◽  
A. A. Kholin ◽  
I. S. Vorobyeva
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Children And Adolescents ◽  
Social Problem ◽  
Clinical Manifestations ◽  
Eeg Activity ◽  
Posttraumatic Epilepsy ◽  
Paroxysmal Disorders

Consequences of traumatic brain injury (TBI) in children and adolescents pose a major medical and social problem, as TBI interferes with neuro ontogenesis. Among these consequences, paroxysmal disorders that manifest in the long-term after TBI represent an important issue. These disorders include posttraumatic headaches, posttraumatic epilepsy and subclinical epileptiform EEG activity. In this review, clinical manifestations, pathophysiology and management of the long-term post-TBI paroxysmal disorders in children and adolescents are discussed.

Sign in / Sign up

Export Citation Format

Share Document